QiagenQGEN
QGEN
About: Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).
Employees: 5,700
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
46% more call options, than puts
Call options by funds: $32.9M | Put options by funds: $22.5M
33% more funds holding in top 10
Funds holding in top 10: 3 [Q4 2024] → 4 (+1) [Q1 2025]
0.15% less ownership
Funds ownership: 66.45% [Q4 2024] → 66.3% (-0.15%) [Q1 2025]
9% less funds holding
Funds holding: 322 [Q4 2024] → 293 (-29) [Q1 2025]
12% less capital invested
Capital invested by funds: $6.6B [Q4 2024] → $5.78B (-$815M) [Q1 2025]
34% less first-time investments, than exits
New positions opened: 44 | Existing positions closed: 67
59% less repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 175
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$43
9%
downside
Avg. target
$43
9%
downside
High target
$43
9%
downside
1 analyst rating
0 positive
0%
1 neutral
100%
0 negative
0%
Baird Catherine Schulte | 9%downside $43 | Neutral Maintained | 21 Apr 2025 |
Financial journalist opinion
Based on 13 articles about QGEN published over the past 30 days
Neutral
Business Wire
8 hours ago
QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
VENLO, Netherlands & WILMINGTON, Del.--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Incyte (Nasdaq: INCY) today announced a new global collaboration to develop a novel diagnostic panel to support Incyte's extensive portfolio of investigational therapies for patients with myeloproliferative neoplasms (MPNs), a group of rare blood cancers, including Incyte's monoclonal antibody INCA033989, targeting mutant calreticulin (mutCALR), which is being developed in myelofi.
Negative
Zacks Investment Research
1 day ago
Should You Add QIAGEN Stock to Your Portfolio for Now?
QGEN rides on test menu growth, strategic partnerships, and strong solvency, despite macro and market headwinds.
Positive
Zacks Investment Research
6 days ago
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
1 week ago
Qiagen (QGEN) Up 8.1% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock?
Neutral
Business Wire
1 week ago
Tracer Biotechnologies Announces Strategic Partnership with QIAGEN to Advance Blood-Based MRD Testing for Solid Tumors
NEW YORK--(BUSINESS WIRE)--Tracer Biotechnologies, a leader in blood-based molecular diagnostics for cancer, is pleased to announce a strategic partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to co-develop and commercialize minimal residual disease (MRD) assays for solid tumors on QIAGEN's QIAcuity digital PCR platform. This collaboration aims to deliver highly sensitive, cost-effective, and decentralized MRD testing solutions that enable oncologists to monitor cancer recurr.
Positive
Zacks Investment Research
1 week ago
Why Qiagen (QGEN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
Here's Why Qiagen (QGEN) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Positive
Zacks Investment Research
1 week ago
QGEN Stock to Gain From Expanding Oncology Portfolio via New Alliances
QIAGEN expands the oncology portfolio with new MRD testing alliances, setting the stage for personalized cancer care and stock growth.
Neutral
Business Wire
1 week ago
QIAGEN expands portfolio for minimal residual disease (MRD) testing in oncology with new strategic partnerships
VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its oncology diagnostics portfolio with two strategic partnerships to advance the use of minimal residual disease (MRD) testing in clinical trials to support pharma co-development projects for companion diagnostics. The new collaborations with Tracer Biotechnologies and Foresight Diagnostics expand QIAGEN's reach in MRD testing and cover solid tumors and hematological cancers.
Neutral
PRNewsWire
1 week ago
Foresight Diagnostics and QIAGEN Announce Strategic Partnership to Advance Development of Companion Diagnostic Kits for Lymphoma
BOULDER, Colo. , Jun 2, 2025 /PRNewswire/ -- Foresight Diagnostics, a leading diagnostics company specializing in ultra-sensitive minimal residual disease (MRD) detection, today announced a strategic, worldwide partnership with QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) to develop and commercialize a kit-based version of Foresight's CLARITY™ assay, with the goal of enabling global in vitro diagnostic (IVD) and companion diagnostic (CDx) applications in lymphoma and other hematological malignancies.
Charts implemented using Lightweight Charts™